FY2025 · ended Dec 31, 2025 · Revenue $44.33B, +5.7% YoY · Filed Feb 20, 2026
Abbott Laboratories (ABT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $44.3 billion and net income of $6.5 billion. Free cash flow was $7.4 billion. As of Sep 30, 2026 it held $5.4 billion in cash and investments and $31.2 billion in total debt.
Revenue (TTM)
$48.23B
+10.0% vs year-ago TTM
Net income (TTM)
$4.70B
-66.4% vs year-ago TTM
Operating cash flow (TTM)
$8.86B
-2.9% vs year-ago TTM
Free cash flow (TTM)
$6.76B
-2.3% vs year-ago TTM
EPS (TTM)
$2.70
-66.1% vs year-ago TTM
Dividend per share (TTM)
$2.52
+6.8% vs year-ago TTM
Shares outstanding
1.74B
+0.2% vs prior year
Net cash
$-25.76B
as of Sep 30, 2026
Operating margin
13.8%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABT (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- IL
- Headquarters
- Abbott Park, IL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1800
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $44.3B | $42.0B | $40.1B | $43.7B | $43.1B |
| Operating income | $8.1B | $6.8B | $6.5B | $8.4B | $8.4B |
| Net income | $6.5B | $13.4B | $5.7B | $6.9B | $7.1B |
| Diluted EPS | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 |
| Operating cash flow | $9.6B | $8.6B | $7.3B | $9.6B | $10.5B |
| Free cash flow | $7.4B | $6.4B | $5.1B | $7.8B | $8.6B |
| Total assets | $86.7B | $81.4B | $73.2B | $74.4B | $75.2B |
| Stockholders' equity | $52.1B | $47.7B | $38.6B | $36.7B | $35.8B |
| Cash and investments | $9.9B | $8.9B | $8.1B | $10.9B | $11.1B |
| Total debt | $14.1B | $15.3B | $15.9B | $17.9B | $19.3B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 21, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 21, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 20, 2026 | Aug 20, 2026 |
| 10-Q | Quarterly report | Jul 28, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 16, 2026 | Jul 16, 2026 |
All 1001 Abbott Laboratories SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.